OPTICAL COHERENCE TOMOGRAPHY to determine if the requirements relating to: age-related macular degeneration for access to initial treatment with ranibizumab or aflibercept, OR diabetic macular oedema for access to initial treatment with ranibizumab, aflibercept or dexamethasone, OR central or branch retinal vein occlusion for access to initial treatment with ranibizumab or aflibercept*, OR vitreomacular traction for access to initial treatment with ocriplasmin, under the Pharmaceutical Benefits Scheme (PBS) are fulfilled. Limited to one service per annum, unilateral or bilateral. Fee: $40.00 *point c) is written in reflection of the PBAC recommendation to add BRVO to the aflibercept listing Category 2 DIAGNOSTIC PROCEDURES AND INVESTIGATIONS – Group D1 MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS – Subgroup 2 - OPHTHALMOLOGY MBS [item number (Note: this will be assigned by the Department if listed on the MBS)] OPTICAL COHERENCE TOMOGRAPHY for the assessment of the need for further treatment following PBS-subsidised ocriplasmin, claimable only once per eye per lifetime. Fee: $40.00 Background The original submission details can be found in the Public Summary Document for Application 1370, comments on Summary Document Applicant’s MSAC’s Public The applicant had no comments. Further information on MSAC MSAC Terms of Reference and other information are available on the MSAC Website at: .
OPTICAL COHERENCE TOMOGRAPHY to determine if the requirements relating to: age-related macular degeneration for access to initial treatment with ranibizumab or aflibercept, OR diabetic macular oedema for access to initial treatment with ranibizumab, aflibercept or dexamethasone, OR central or branch retinal vein occlusion for access to initial treatment with ranibizumab or aflibercept*, OR vitreomacular traction for access to initial treatment with ocriplasmin, under the Pharmaceutical Benefits Scheme (PBS) are fulfilled. Limited to one service per annum, unilateral or bilateral. Fee: $40.00 *point c) is written in reflection of the PBAC recommendation to add BRVO to the aflibercept listing Category 2 – DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Group D1 – MISCELLANEOUS DIAGNOSTIC PROCEDURES AND INVESTIGATIONS Subgroup 2 - OPHTHALMOLOGY MBS [item number (Note: this will be assigned by the Department if listed on the MBS)] OPTICAL COHERENCE TOMOGRAPHY for the assessment of the need for further treatment following PBS-subsidised ocriplasmin, claimable only once per eye per lifetime. Fee: $40.00 Background The original submission details can be found in the Public Summary Document for Application 1370, Applicant’s comments on MSAC’s Public Summary Document The applicant had no comments. Further information on MSAC MSAC Terms of Reference and other information are available on the MSAC Website at: .
FINAL_PSD-1370_March2016_Ocriplasmin_for%20symptomatic_vitreomacular_adhesion-Accessible.docx